{"id":"minoxidil-5-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Scalp irritation"},{"rate":null,"effect":"Dryness of scalp"},{"rate":null,"effect":"Itching"},{"rate":null,"effect":"Unwanted hair growth on face or body"},{"rate":null,"effect":"Tachycardia (with systemic absorption)"}]},"_chembl":null,"_dailymed":{"setId":"4dc2850a-9a7e-660f-e063-6294a90afd94","title":"TACRUITF 5% MINOXIDIL WITH BIOTIN TOPICAL SOLUTION (MINOXIDIL) SOLUTION [GUANGZHOU BORDERLESS TECHNOLOGY CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, increasing vasodilation and blood flow to the scalp. This enhanced perfusion delivers more oxygen and nutrients to hair follicles, stimulating them to transition from the telogen (resting) phase to the anagen (active growth) phase, thereby promoting hair regrowth and slowing hair loss.","oneSentence":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:01:30.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male pattern baldness)"},{"name":"Female pattern hair loss"}]},"trialDetails":[{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":"Androgenic Alopecia","enrollment":420},{"nctId":"NCT07373054","phase":"NA","title":"Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-11-06","conditions":"Androgenic Alopecia","enrollment":18},{"nctId":"NCT07370519","phase":"PHASE2","title":"Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2026-01-25","conditions":"Androgenetic Alopecia (AGA)","enrollment":388},{"nctId":"NCT07203599","phase":"PHASE1, PHASE2","title":"A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","status":"RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2025-09-20","conditions":"Androgenic Alopecia","enrollment":59},{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":250},{"nctId":"NCT06813963","phase":"PHASE4","title":"Minoxidil for Treating White Hair: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Southern Medical University, China","startDate":"2025-02-15","conditions":"Grey Hair","enrollment":100},{"nctId":"NCT07056933","phase":"NA","title":"Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-07-08","conditions":"Alopecia","enrollment":25},{"nctId":"NCT07011485","phase":"PHASE2","title":"A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDFE Pharma Innovations FZCO","startDate":"2025-05-14","conditions":"Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)","enrollment":15},{"nctId":"NCT04721548","phase":"PHASE3","title":"Treatment of Androgenetic Alopecia in Men for 24 Weeks","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2023-03-02","conditions":"Alopecia","enrollment":336},{"nctId":"NCT06501924","phase":"PHASE3","title":"Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","status":"NOT_YET_RECRUITING","sponsor":"Applied Biology, Inc.","startDate":"2025-01-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness","enrollment":516},{"nctId":"NCT06015516","phase":"PHASE1","title":"Bioavailability Clinical Trial of Oral Minoxidil 1 mg","status":"COMPLETED","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-02-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT05636904","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men","status":"COMPLETED","sponsor":"Dermaliq Therapeutics, Inc.","startDate":"2022-12-05","conditions":"Androgenetic Alopecia","enrollment":120},{"nctId":"NCT06333600","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss","status":"RECRUITING","sponsor":"Sohag University","startDate":"2023-05-20","conditions":"Dermatology, Female Pattern Baldness","enrollment":45},{"nctId":"NCT06218394","phase":"NA","title":"Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-12-14","conditions":"Androgenetic Alopecia","enrollment":135},{"nctId":"NCT06108193","phase":"PHASE1, PHASE2","title":"Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-07-11","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT06066827","phase":"NA","title":"Hair Regeneration in Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","startDate":"2023-08-14","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT05989165","phase":"PHASE3","title":"Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-06-01","conditions":"Androgenetic Alopecia","enrollment":36},{"nctId":"NCT03852992","phase":"PHASE2","title":"Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2022-09-30","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness","enrollment":""},{"nctId":"NCT02460289","phase":"NA","title":"Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-05-19","conditions":"Male Pattern of Hair Loss, Androgenic Alopecia","enrollment":63},{"nctId":"NCT05681897","phase":"NA","title":"Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-02","conditions":"Alopecia, Androgenetic","enrollment":30},{"nctId":"NCT03753113","phase":"PHASE3","title":"Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%","status":"COMPLETED","sponsor":"Farid Masoud","startDate":"2018-11-28","conditions":"Androgenetic Alopecia","enrollment":24},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT02279823","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","startDate":"2014-10","conditions":"Androgenetic Alopecia","enrollment":95},{"nctId":"NCT02486848","phase":"NA","title":"Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil","status":"WITHDRAWN","sponsor":"Maja Kovacevic, MD","startDate":"2016-06","conditions":"Female Pattern Hair Loss, Androgenetic Alopecia","enrollment":""},{"nctId":"NCT01145625","phase":"PHASE3","title":"Clinical Trial in Females With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-06","conditions":"Alopecia","enrollment":322},{"nctId":"NCT01325337","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-06","conditions":"Alopecia, Alopecia, Androgenetic, Baldness","enrollment":307},{"nctId":"NCT01662089","phase":"PHASE1, PHASE2","title":"The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement","status":"UNKNOWN","sponsor":"Siriraj Hospital","startDate":"2012-01","conditions":"Female Pattern Alopecia","enrollment":20},{"nctId":"NCT01650272","phase":"PHASE1, PHASE2","title":"Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Siriraj Hospital","startDate":"2012-06","conditions":"Objective (Goal), Self-Assessment, Adverse Effects","enrollment":20},{"nctId":"NCT00958750","phase":"PHASE3","title":"Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2008-06","conditions":"Androgenetic Alopecia, Female Pattern Hair Loss","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rogaine®","Regaine®"],"phase":"marketed","status":"active","brandName":"minoxidil 5% solution","genericName":"minoxidil 5% solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Female pattern hair loss.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}